A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil

American Journal of Geriatric Psychiatry

Volumn 14, Issue 5, 2006, Pages 428-437

  Van Dyck, Christopher H ^a,d   Schmitt, Frederick A ^b   Olin, Jason T ^c  

^a YALE UNIVERSITY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c FOREST RESEARCH INSTITUTE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer disease; Memantine; NMDA receptor antagonist

Indexed keywords

DONEPEZIL; MEMANTINE; PLACEBO;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIAGNOSTIC VALUE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG STABILITY; EVALUATION RESEARCH; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; OUTCOMES RESEARCH; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 33646459451     PISSN: 10647481     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.JGP.0000203151.17311.38     Document Type: Article

References (27)

1. Leber P: Guidelines for the Clinical Evaluation of Antidementia Drugs, 1st draft. Rockville, MD, US Food and Drug Administration, 1990
2. Winblad B, Brodaty H, Gauthier S, et al: Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry 2001; 16:653-666
3. Cummings JL: Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry 2003; 11:131-145
4. Lanctôt KL, Herrmann N, Yau KK, et al: Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 2003; 169:557-564
5. Doraiswamy PM, Kaiser L, Bieber F, et al: The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease. Alzheimer Dis Assoc Disord 2001; 15:174-183
6. Teri L: Behavior and caregiver burden: behavioral problems in patients with Alzheimer disease and its association with caregiver distress. Alzheimer Dis Assoc Disord 1997; 11(suppl 4):35-38
7. Steele C, Rovner B, Chase GA, et al: Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 1990; 147:1049-1051
8. European Medicine Evaluation Agency (EMEA); Note for Guidance on Medicinal Products in the Treatment of Alzheimer's Disease. London, EMEA, 1997.
9. Reisberg B, Doody R, Stöffler A, et al: Memantine in moderate-to severe Alzheimer's disease. N Engl J Med 2003; 348:1333-1341
10. Namenda, package insert. New York, Forest Laboratories, Inc., 2003
11. Greenamyre JT, Maragos WF, Albin RL, et al: Glutamate transmission and toxicity in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12:421-430
12. Danysz W, Parsons CG, Möbius HJ, et al: Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease-a unified glutamatergic hypothesis on the mechanism of action. Neurotox Res 2000; 2:85-97
13. Peskind E, Potkin S, Pomara N, et al: Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: a randomized controlled trial [Abstract]. Eur J Neurol 2004; 11(suppl 2):187.
14. Tariot PN, Farlow MR, Grossberg GT, et al: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291:317-324
15. Winblad B, Poritis N: Memantine in severe dementia: results of the M-BEST Study (Benefit and Efficacy in Severely demented patients during Treatment with memantine). Int J Geriatr Psychiatry 1999; 14:135-146
16. McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-944
17. Folstein MF, Folstein SE McHugh PR: 'Mini-Mental State.' A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198
18. Schmitt FA, Ashford W, Ernesto C, et al: The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(suppl 2):51-56.
19. Galasko D, Schmitt F, Thomas R, et al: Detailed assessment of acthities of daily living in moderate to severe Alzheimer's disease. J Int Neuropsychol Soc 2005; 11:446-453
20. Schneider LS, Olin JT, Doody RS, et al: Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(suppl 2):22-32.
21. Cummings JL, Mega M, Gray K, et al: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44:2308-2314
22. Zeger SL, Liang KY: Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42:121-130
23. Guyatt GH, Sackett DL, Cook DJ: Users' guides to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group. JAMA 1994; 271:59-63
24. Cook RJ, Sackett DL: The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995; 310:452-454
25. Feldman H, Gauthier S, Hecker J, et al: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001; 57:613-620
26. Ismail MS, Tariot PN: Alzheimer's disease. Bridging the gap between clinical studies and clinical practice. Practical Neurology 2002; 2:30-35
27. Livingston G, Katona C: The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis. Int J Gedatr Psychiatry 2004; 19:919-925